MetaCap

TuHURA Biosciences (HURA) vs Nkarta (NKTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TuHURA Biosciences (HURA) has outperformed Nkarta (NKTX) over the past year, losing 28.2% versus a loss of 36.9%. Over five years, NKTX leads with a -93.0% price change compared with -99.9% for HURA. TuHURA Biosciences is the larger company by market cap ($82.2 million vs $81.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HURA-28.16%NKTX-36.94%
+113%+15%-84%
Nov 21, 20251 yearNov 20, 2026
HURA-99.91%NKTX-93.47%
+11%-47%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HURA versus NKTX key metrics
MetricHURANKTX
Share price$1.25$1.14
Market cap$82.20M$81.29M
1-day change-8.09%+1.34%
YTD return+65.13%-38.65%
1-year return-28.16%-36.94%
5-year return-99.91%-93.05%
EPS (TTM)$-0.50$-1.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$0
Net income (latest FY)$-30.05M$-104.08M
52-week high$3.43$3.72
52-week low$0.41$1.11
Distance from 52-week high-63.56%-69.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+543.20%+825.11%
Average volume329.76K1.02M
Shares outstanding65.76M71.62M
Employees22108
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About TuHURA Biosciences

HURA stock →

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

About Nkarta

NKTX stock →

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.

Health Care · Biotechnology: Pharmaceutical Preparations · 108 employees

HURA vs NKTX FAQ

Which is bigger, TuHURA Biosciences or Nkarta?

TuHURA Biosciences (HURA) is larger, with a market capitalization of $82.20M compared with $81.29M for Nkarta (NKTX).

Which stock has performed better over the past year, HURA or NKTX?

HURA returned -28.16% over the past 12 months, compared with -36.94% for NKTX (price return, excluding dividends). Past performance does not predict future results.

Are TuHURA Biosciences and Nkarta in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons